Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] TAS5315 in Healthy Adults
jRCT2071230061Phase 1Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAS5315, sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoints: Plasma and blood radioactivity and TAS5315 pharmacokinetics, Urinary and fecal excretion of radioactivity and 2 more. Started Oct 2023; status: completed.
02
Drugs
TAS5315
Beyond the preview
Go deeper on jRCT2071230061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230061.